Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

CHF: full-pipeline trial registry

2 of 6 indexed CHF trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count

CHF: 6 US clinical trials tracked, 2 recruiting.

CHF is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Nile Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition chf

OPEN 2 | RECR 33% | LATE 1 | EARLY 1 | RANK #2866 | SPON 1

Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%CHF (this)33%
Open-enrollment share among volume-matched conditions near CHF

CHF lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for CHF on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. CHF is recruiting below its size-band peers.

    2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates CHF research.

    Nile Therapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical CHF enrolment sits around 135 participants.

    Median target enrolment is 135 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. CHF splits between interventional and observational designs.

    4 interventional and 2 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 41

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 4 1

Named interventions

Most-linked intervention names on CHF records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

IV loop diuretic Drug
1 trials
Active attention control Behavioral
1 trials
Technology-assisted care transition intervention Behavioral
1 trials
Cenderitide Drug
1 trials
NxStage System One Device
1 trials
sample analysis Other
1 trials
Revivent System Device
1 trials
Placebo Other
1 trials

US sites by state

Facility locations filed on CHF trials. A trial with sites in several states counts in each.

Minnesota 2 trials
Massachusetts 2 trials
Illinois 2 trials
Florida 2 trials
California 2 trials
Pennsylvania 1 trials
Oklahoma 1 trials
Ohio 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this CHF page

6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CHF condition card totals 6 registered trials; most-linked intervention IV loop diuretic; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.